Stephen Joseph Elliman

This inventor holds 15 USPTO granted patents and 5 published patent applications, plus 2 CIPO patents and 6 EPO patents. Top assignee: Orbsen Therapeutics Limited. Active years: 2018-2024.

USPTO Granted Patents = 15 (Patent Applications = 5)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 6 (Patent Applications = 6)

Average Co-Inventor Count = 1.2

ph-index = 5

Forward Citations = 52(Granted Patents)

Location History:

Rosscahil, IE (2022)
Galway, IE (2018 - 2024)

Company Filing History:

15 out of 15

Orbsen Therapeutics Limited

patents

Years Active: 2018-2024

Loading Chart...

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11952590 - Stromal stem cells (2024-04-09),

2. 11952589 - Stromal stem cells (2024-04-09),

3. 11926848 - Stromal stem cells (2024-03-12),

4. 11918687 - SDC-2 exosome compositions and methods of isolation and use (2024-03-05),

5. 11903997 - Modulators of syndecan-2 and uses thereof (2024-02-20),

6. 11884936 - Stromal stem cells (2024-01-30),

7. 11434471 - Stromal stem cells (2022-09-06),

8. 11268067 - Methods of isolation and use of CD39 stromal stem cells (2022-03-08),

9. 11230700 - Stromal stem cells (2022-01-25),

10. 11142747 - Stromal stem cells (2021-10-12),

11. 11026994 - Syndecan-2 compositions and methods of use (2021-06-08),

12. 10920197 - Stromal stem cells (2021-02-16),

13. 10907131 - Stromal stem cells (2021-02-02),

14. 10251934 - Syndecan-2 compositions and methods of use (2019-04-09),

15. 10124038 - Modulators of syndecan-2 and uses thereof (2018-11-13),

Title: The Innovative Contributions of Stephen Joseph Elliman

Introduction

Stephen Joseph Elliman is a prominent inventor based in Galway, Ireland. He has made significant contributions to the field of stem cell research, holding a total of 15 patents. His work focuses on the isolation and application of stromal stem cells, which have potential therapeutic uses.

Latest Patents

Elliman's latest patents revolve around the isolation of stromal stem cells from human bone marrow. These cells are expanded into clonal populations and cultured for various applications. The isolation process is based on the expression of a specific cell surface marker that binds to an antibody. This antibody cross-reacts with cell surface markers found on mouse and rat stromal stem cells, as well as other mammalian species such as horses, rabbits, and pigs. Notably, useful stromal stem cell populations are identified as being positive for SDC2.

Career Highlights

Elliman is currently associated with Orbsen Therapeutics Limited, where he continues to advance his research in stem cell technology. His innovative approaches have positioned him as a key figure in the field, contributing to the understanding and application of stem cells in medicine.

Collaborations

Elliman collaborates with notable colleagues, including Jack Kavanaugh and Laura Rose Barkley. Their combined expertise enhances the research and development efforts at Orbsen Therapeutics Limited.

Conclusion

Stephen Joseph Elliman's work in the field of stem cell research exemplifies innovation and dedication. His contributions through patents and collaborations continue to pave the way for advancements in medical science.